Ovarian carcinoma tumor

Melphalan is an antineoplastic drug, listed also as a Class I immunosuppressive agent (effective only when given prior to the immune stimulus) [1]. It is used for the treatment of multiple myeloma, ovarian carcinoma, tumors of the testes, chronic granulocytic leukemia, chronic lymphocytic leukemia, seminoma, Ewing s sarcoma, reticulum cell sarcoma, and thymoma [1,2]. Its use as an adjuvant to surgery in the management of primary breast cancer was one of the first illustrations of the therapeutic potential of combined modalities of treatment [3]. 

Intraperitoneal administration of chemotherapeutic agents has been used for many years as a way of increasing the delivery of drugs to tumors (e.g., ovarian carcinoma) located in the peritoneal cavity (Markman, 1986 Howell and Zimra, 1988). Cisplatin (Casper et al., 1983 Markman et al., 1985), cytosine arabinoside (Ara-C) (King et al., 1984 Markman et al., 1985, 1986), and bleomycin (Markman et al., 1986) are examples of intraperitoneally administered drugs which were already successfully applied in clinical settings. 

As described in several monographs [4], bryostatin 1 exhibits significant in vitro and in vivo antineoplastic activity against a range of tumor cell lines including murine leukemia, B-cell lymphoma, reticulum cell sarcoma, ovarian carcinoma, and melanoma. It is also effective in the modulation of apoptotic function [5], the reversal of multidrug resistance [6], and stimulation of the immune system [7]. These unique features displayed by bryostatin 1 are attributed to its high affinity for protein kinase C (PKC) isozymes and its ability to selectively modulate their functions [8]. PKCs are a type of intracellular serine and threonine kinase that... 

Denkert C, Budczies J, Kind T, et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res. 2006 66 10795-10804. 

Blood vessels penetrating tumors provide malignant cells with another point at which to enter the circulation. Evidence exists that in situation where cancers disseminate predominantly by the blood, the extent of metastasis depends upon the vasculature of the primary tumor. Thin-walled capillaries, especially those newly formed, provide poor resistance to invading cancer cells. Also, data from microscopy studies show that the endothelium of tumor vessels, particularly in areas of poor oxygenation, is often abnormal (Kl). These abnormalities may permit invasion by neoplastic cells (P3). Finally, tumors can spread by direct extension into body cavities such as pleural and peritoneal spaces. An example of this is the formation of peritoneal metastases from ovarian carcinoma. 

As might be expected from a screen in which the target tumor was a soft tissue sarcoma, those tumors were among the most sensitive to the compound, along with ovarian tumors, mesotheliomas, melanomas, and lung carcinomas. Tumors least sensitive to this compound included pancreatic carcinomas, neuroblastomas, and especially, renal cell carcinomas. As a rule, for the seven classes of compounds identified in the screen, soft tissue sarcomas, ovarian carcinomas, and mesotheliomas were the most sensitive tumor types. 

Matthews, N., Neale, M.L., Jackson, S.K., and Stark, J.M., 1987, Tumor cell kilhng by tumor necrosis factor inhibition by anearobiotic condition, free-radical scavengers and inhibitors of arachidonate metabolism. Immunology 62 153-155 Miller, M.G., Rodgers, A., and Cohen, G.M., 1986, Mechanisms oftoxicity of naphthoquinones to isolated hepatocytes. Biochem. Pharmacol. 35 1177-1184 Minko, T., Kopeckova, P., and Kopecek, J., 1999, Comparison ofthe anticancer effect of free and HPMA copolymer-bound adtiamycin in human ovarian carcinoma cells. Pharmaceut. Res. 16 986-996... 

The toxicity of the four purified cytochalasins (61—64) was measured against human tumor cell lines 2780S (ovarian carcinoma), SW-620... 

Variations on the filter-based assay have been designed to approximate more physiological contexts. Such assays include tumor cell invasion across a confluent cell monolayer (e.g., endothelial cells (EC) as a surrogate for intravasation or extravasation during hematogenous metastasis (24)) and ovarian carcinoma invasion of mesothelial cell monolayers (25). Additionally, 1 mm thick slices of human brain tissue have been used as a tissue barrier on Transwell filters with invasion of GFP-labeled glioma cells measured by confocal microscopy (26). 

Intracavitary administration of various agents has been used for patients with malignant pleural or peritoneal effusions. Intraperitoneal instillations of cisplatin, etoposide, bleomycin, 5-fluorouracil, and interferon are well tolerated and are being evaluated in patients with ovarian carcinomas, in whom the tumor is frequently restricted to the peritoneal cavity. 

Despite its lower chemical reactivity, carboplatin has antitumor activity that is similar to that of cisplatin against ovarian carcinomas, small cell lung cancers, and germ cell cancers of the testis. Most tumors that are resistant to cisplatin are cross-resistant to carboplatin. 

It is indicated in GI tract carcinoma, acute myeloblastic leukaemia, bronchogenic, breast and ovarian carcinoma, soft tissue and bone sarcomas, malignant lymphoma primary management of nonmetastatic bladder carcinoma (intravesical administration), Wilm s tumor and neuroblastoma. 

Twenty-five cryptophycins, e.g. cryptophycin 1 (162), have been isolated from a Nostoc sp. strain. They exhibit various degrees of cytotoxicity against three tumor cell lines, namely KB (human nasopharyngeal), LoVo (human colorectal adenocarcenoma), and SKOV3 (human ovarian carcinoma). Removal of the chlorine atom leads to a 10-fold reduction in cytotoxicity [124]. The antitumor activity of a number of cryptophycins from Nostoc sp. has been evaluated [125]. 

Ovarian carcinoma occurred in an adolescent girl with a suggestive history. The tumor was a small-cell carcinoma of the ovary, which is excessively rare in childhood and adolescence (47). Her grandmother had... 

Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK. 2007. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 13 3423-3430. 

A Phase I clinical study was carried out in four ovarian cancer patients to exploit the drug targeting ability of cholesterol-rich emulsions to LDL receptors of tumor cells. UptakiHjf [ etoposide oleate and fc] cholesterol oleate were 4.1 times and 4.9 times, respectively, greater than that in contralateral normal ovaries. This indicates that most ofthe etoposide is retained in the emulsion before its internalization by the tumor cells and shows the ability of ofthe cholesterol-rich emulsions to concentrate in ovarian carcinomas (Azevedo et al., 2005). 

Azevedo, C.H.M., Carvalho, J.P., Valduga, C.J., and Maranhao, R.C. (2005) Plasma kinetics and uptake by the tumor of a cholesterol-rich microemulsion (LDE) associated to etoposide oleatein patient with ovarian carcinoma.Gynecol. Oncol., 97 178-182. 

Like patients with breast carcinoma, those with ovarian cancer may benefit from treatment with Herceptin in combination with chemotherapeutic drugs. Herceptin treatment is effective, in both early and advanced stages of ovarian cancer (when the majority of tumor cells express HER-2 protein), for eliminating the potentially more malignant HER-2-positive tumor cells. The effectiveness of Herceptin is based on the affinity of this monoclonal antibody for the extracellular domain of HER-2, which is common as ovarian carcinomas progress. However, a tumor vaccine inducing antibody and/or T-cell immunity to HER-2 epitopes will ultimately provide the most effective means to prevent the emergence of HER-2-positive cells. 

Davidson, B., Berner, A., Nesland, J. M., Risberg, B., Kristensen, G. B., Trope, C. G., and Bryne, M. 2000. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma Evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions. Hum. Pathol. 37 1081-1087. 

The in vivo antitumor activity of 78 was evaluated against A151 human ovarian carcinoma xenograft in nude athymic mice, and was found to be equivalent or slightly better than that of paclitaxel, causing total regression of the tumor.94... 

---